高级检索
当前位置: 首页 > 详情页

Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression

文献详情

资源类型:
Pubmed体系:
机构: [1]School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710071, China. [2]West China Biomedical Big Data Centre, West China Hospital of Sichuan University, Chengdu 610041, China. [3]Center for Computational Systems Medicine, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. [4]School of Pharmacy, Shaanxi Institute of International Trade and Commerce, Xianyang, Shaanxi 712046, China.
出处:
ISSN:

摘要:
Disrupted alternative polyadenylation (APA) is frequently involved in tumorigenesis and cancer progression by regulating the gene expression of oncogenes and tumor suppressors. However, limited knowledge of tumor-type- and cell-type-specific APA events may lead to novel APA events and their functions being overlooked. Here, we compared APA events across different cell types in non-small cell lung cancer (NSCLC) and normal tissues and identified functionally related APA events in NSCLC. We found several cell-specific 3'-UTR alterations that regulate gene expression changes showed prognostic value in NSCLC. We further investigated the function of APA-mediated 3'-UTR shortening through loss of microRNA (miRNA)-binding sites, and we identified and experimentally validated several oncogene-miRNA-tumor suppressor axes. According to our analyses, we found SPARC as an APA-regulated oncogene in cancer-associated fibroblasts in NSCLC. Knockdown of SPARC attenuates lung cancer cell invasion and metastasis. Moreover, we found high SPARC expression associated with resistance to several drugs except cisplatin. NSCLC patients with high SPARC expression could benefit more compared to low-SPARC-expression patients with cisplatin treatment. Overall, our comprehensive analysis of cell-specific APA events shed light on the regulatory mechanism of cell-specific oncogenes and provided opportunities for combination of APA-regulated therapeutic target and cell-specific therapy development.© 2023 The Authors.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
第一作者:
第一作者机构: [1]School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710071, China. [2]West China Biomedical Big Data Centre, West China Hospital of Sichuan University, Chengdu 610041, China. [3]Center for Computational Systems Medicine, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
共同第一作者:
通讯作者:
通讯机构: [1]School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710071, China. [3]Center for Computational Systems Medicine, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. [4]School of Pharmacy, Shaanxi Institute of International Trade and Commerce, Xianyang, Shaanxi 712046, China. [*1]School of Life Science and Technology, Xidian University, Xi’an, Shaanxi 710071, China [*2]Center for Computational Systems Medicine, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号